Navigation Links
Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA
Date:5/24/2013

rand is manufactured in California, USA and Vestiage has a distribution agreement for the brand allowing Vestiage to sell online, and through spas, salons, resorts, all retailers, and physicians both in the US and certain other countries. The Vestiage Territory Program awards exclusive Vestiage Metropolitan Statistical Areas ("MSA's") to qualified companies or individuals that sell to salons, spas, retailers, resorts and physicians in each MSA territory. Vestiage provides product literature, retail displays, product training, and marketing/sales support. The most lucrative MSA's in major cities are available to the most qualified organizations/individuals and will likely be in very high demand. The extremely low cost and high revenue potential of each MSA territory and the ability to control an attractive Vestiage MSA that can generate millions in revenue annually is expected to be the attraction.

"If you have the ability to sell, or you're already selling to the spa and salon channel, Vestiage gives you the ability to sell the most sophisticated and advanced science in skin care to the independent retailers, prestige salons, spas, and physicians with very little investment on your part. We are not charging for the MSA territory. We pay for all the product that is sold by each MSA 'manager' so our MSA 'managers' never have to come out of pocket and buy product from us. We provide marketing materials, retail displays, pay for the product that is ordered, ship to the buyers, and pay the MSA 'manager' a commission on all sales in the MSA that they generate. We further support the salon or spa with a media and publicity campaign that highlights their business in the press and drives customers to them. We suspect that our average territory will be able to create a revenue stream of $1 million or more annually to the MSA 'manager' and some perhaps much more. These are large territories so people can rea
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Vestiage Announces Initial Advisory Board Members
2. Vestiage Signs Buyside Engagement Agreement with CJK Securities
3. Vestiage Announces Key Partners for Launch of Monterey Bay Nutraceuticals Anti-Aging Wellness Products
4. Vestiage Announces Filing of Disclosure Statement with Exchange
5. Vestiage CEO Comments on Immortal Life
6. Vestiage to Partner with Skincare By Alana
7. Venaxis Announces Pricing of Offering of Common Stock and Warrants
8. Pusan National University Announces Science Translational Medicine Publication Highlighting Landmark Demonstration of Functional Anti-Cancer Antibody Induction in Patients Following JX-594 Treatment
9. PHI Emergency Management on Announces Father's Day Specials All Emergency Survival Kits
10. Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC
11. Emerson Resources Announces CEO Retirement and Appointment of Successor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... British Columbia and MENLO PARK, ... Pharmaceuticals, Inc. (OTCQX: DMPI) (DelMar and the Company), ... cancer therapies in new orphan drug indications, today announced ... been added as a clinical trial site for the ... with refractory glioblastoma multiforme (GBM), the most common and ...
(Date:4/16/2015)... 16, 2015  Northwest Biotherapeutics, Inc. (NASDAQ: ... non-toxic DCVax® personalized immune therapies for cancer, announced ... Loncar Cancer Immunotherapy Index (LCINDX), a professional index ... immunotherapy field within the biotechnology space.  ... 25 companies" in the immunotherapy space, including 6 ...
(Date:4/16/2015)... (PRWEB) April 16, 2015 Modality ... management systems for highly regulated industries, is pleased ... name a monthly columnist for Cold Chain IQ ... http://www.coldchainiq.com ). His column titled, Global Cold Chain ... information for today’s life sciences, pharmaceutical and healthcare ...
(Date:4/15/2015)... April 16, 2015 Immunocore ... drugs to treat cancer and other diseases, and ... of AstraZeneca, today announced that they have entered ... terms of the agreement, Immunocore will conduct a ... inhibitors MEDI4736 (anti-PD-L1) and/or tremelimumab (anti-CTLA-4) with IMCgp100, ...
Breaking Biology Technology:DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 2DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 3DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 4DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 5NW Bio Included In New Index Of The "Top 25 Cancer Immunotherapy Companies" 2NW Bio Included In New Index Of The "Top 25 Cancer Immunotherapy Companies" 3Modality Solutions Gary Hutchinson Named Columnist for Cold Chain IQ 2Modality Solutions Gary Hutchinson Named Columnist for Cold Chain IQ 3Immunocore and MedImmune Announce New Collaboration to Conduct Immuno-oncology Combination Trails in Melanoma 2Immunocore and MedImmune Announce New Collaboration to Conduct Immuno-oncology Combination Trails in Melanoma 3Immunocore and MedImmune Announce New Collaboration to Conduct Immuno-oncology Combination Trails in Melanoma 4Immunocore and MedImmune Announce New Collaboration to Conduct Immuno-oncology Combination Trails in Melanoma 5Immunocore and MedImmune Announce New Collaboration to Conduct Immuno-oncology Combination Trails in Melanoma 6
... by Stent Manufacturers Expected to ... - Witness Live Case Examples of Advanced Practices by Leading, Interventionalists, Broadcast from ... the Role of IVUS in Improving Stent, Results. - See How Many of the ... ...
... 22 Agendia BV, a,world leader in the rapidly ... Chief Research Officer Laura van ,t Veer has,received a ... Ribbon Breast Cancer Research Foundation. The Pink Ribbon ... 151 international breast cancer researchers with a total value ...
... CAMBRIDGE, Mass., Oct. 22 Genzyme Corp.,(Nasdaq: ... and Drug Administration,has granted marketing approval for Renvela(TM) ... patients with chronic kidney disease on,dialysis. Renvela is ... phosphate binder in the United States. "Since ...
Cached Biology Technology:Volcano Announces Activities at TCT 2007: Expanded Role of IVUS in PCI to be Demonstrated 2Volcano Announces Activities at TCT 2007: Expanded Role of IVUS in PCI to be Demonstrated 3Volcano Announces Activities at TCT 2007: Expanded Role of IVUS in PCI to be Demonstrated 4Agendia BV Announces That its Chief Research Officer Laura van 't Veer has Received a 2007 Breast Cancer Research Foundation Award 2FDA Approves Genzyme's Renvela(TM) for Dialysis Patients 2FDA Approves Genzyme's Renvela(TM) for Dialysis Patients 3FDA Approves Genzyme's Renvela(TM) for Dialysis Patients 4FDA Approves Genzyme's Renvela(TM) for Dialysis Patients 5
(Date:3/24/2015)... , March 24, 2015   NexID Biometrics ... with critical security-authentication needs, today announced the beginning of ... (FFD) solution. The company, based in ... at the three-day Connect:ID Expo, which began here today ... NexID said version 2.0 of its SDK boosts the ...
(Date:3/23/2015)...   HOYOS Labs , a leading global authentication ... the Company will demonstrate multiple biometrics-based technologies under its ... Connect:ID on March 23 through 25, 2015, in ... the IEEE Biometric Open Protocol Standard; free biometrics-based consumer ... control system. BOPS was invented by HOYOS Labs and ...
(Date:3/20/2015)... , Mar. 20, 2015 Research and Markets ... addition of the "India Sensors Market Forecast ... The sensor market is projected to ... Consumer electronics, automotive, industrial and healthcare ... in the country. In addition, adoption of MEMS ...
Breaking Biology News(10 mins):NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 2India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 3
... at Loyola University Chicago Stritch School of Medicine have ... Institutes of Health to study vitamin D deficiency in ... relation between low vitamin D levels and risks for ... Evidence from numerous previous studies is "inconclusive and needs ...
... WEST LAFAYETTE, Ind. - A Purdue University researcher has ... might lead to improvements in that and other crops. ... landscape architecture, wanted to understand the relationship between natural ... plant architecture, specifically plant height. Schulz said corn could ...
... at the University of North Carolina at Chapel Hill have ... different viruses in an effort to create the ultimate vehicle ... investigators found no side effects from using a "chimeric" virus ... patients with muscular dystrophy. "This trial demonstrates that gene ...
Cached Biology News:Loyola receives NIH grant to study vitamin D deficiency in African populations 2Stronger corn? Take it off steroids, make it all female 2Stronger corn? Take it off steroids, make it all female 3Clinical trial for muscular dystrophy demonstrates safety of customized gene therapy 2
... Agencourt offers pre-validated ... over 1500 amplicons within ... serine/threonin kinases, and more ... These assays were ...
... 384-Well Microarray plates are ideal for use as ... liquid handling applications (down to 5µl). These plates ... well design. Features 384 ... available 70µl well volume (cylindrical well), 55µl ...
Anti-Phospho-JKK/SEK1/MKK4 pAb Description: 100 g rabbit polyclonal antibody. Reacts with human/mouse/rat. Tested in WB. Research Focus: signal transduction Storage: -20C Shipping Tem...
...
Biology Products: